Home > Insider Trading > Filing (0001104659-13-083704)

Filing Details

Issuer

Cik	Name	Symbol	Sector (SIC)	IRS No
881524	Vivus Inc	VVUS	Pharmaceutical Preparations (2834)	943136179

Insiders

Cik	Name	Reported Address	Insider Title	Director	Officer	Large Shareholder	Other
1361754	J Alexander Denner	C/O Sarissa Capital Management Lp 660 Steamboat Road, 3Rd Floor Greenwich CT 06830		Yes	No	No	No

Reported Non-Derivative Transactions

Sec. Name	Acquisiton - Disposition	Date	Amount	Price	Remaning Holdings	Equity Swap Involved	Form Type	Code	Nature of Ownership	Explanation
Common Stock	Acquisiton	2013-11-08	417,068	$8.52	2,424,167	No	4	P	Indirect	See footnotes
Common Stock	Acquisiton	2013-11-11	149,776	$8.78	2,573,943	No	4	P	Indirect	See footnotes

Equity Swap Involved	Form Type	Code	Nature of Ownership	Explanation
No	4	P	Indirect	See footnotes
No	4	P	Indirect	See footnotes

Footnotes

On November 8, 2013, Sarissa Capital Domestic Fund LP, a Delaware limited partnership ("Sarissa Domestic"), purchased an aggregate of 417,068 shares of common stock of VIVUS, Inc.
On November 11, 2013, Sarissa Domestic purchased an aggregate of 140,961 shares of common stock of VIVUS, Inc. and Sarissa Capital Offshore Master Fund LP, a Cayman Islands exempted limited partnership ("Sarissa Offshore"), purchased an aggregate of 8,815 shares of common stock of VIVUS, Inc.
Of these shares, Sarissa Domestic directly beneficially owns 1,540,505 shares and Sarissa Offshore directly beneficially owns 1,033,438 shares. Sarissa Offshore and Sarissa Domestic are collectively referred to herein as the "Sarissa Funds".
Sarissa Capital Management GP LLC, a Delaware limited liability company ("Sarissa Capital GP"), is the general partner of Sarissa Capital Management LP, a Delaware limited partnership ("Sarissa Capital"), the investment advisor to the Sarissa Funds. Dr. Denner is the Chief Investment Officer of Sarissa Capital and the managing member of Sarissa Capital GP. By virtue of the foregoing, Dr. Denner may be deemed to indirectly beneficially own (as that term is defined in Rule 13d-3 of the Securities Exchange Act of 1934, as amended) the shares that the Sarissa Funds directly beneficially own.
Dr. Denner disclaims beneficial ownership of the shares being reported on this Form 4 except to the extent of his pecuniary interest therein.